[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360243-105":59,"doc-detail-360243-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-determinants-of-thyroid-cancer-progression-thyroid-hormone-signaling-the-brafmapk-pathway-and-emerging-mirna-biomarkers","Molecular Determinants of Thyroid Cancer Progression - Thyroid Hormone Signaling, the BRAF/MAPK Pathway, and Emerging miRNA Biomarkers","","Thyroid cancer is the most common malignancy of the endocrine system and represents a biologically heterogeneous disease driven by endocrine regulation, oncogenic signaling, and tumor microenvironment dynamics. Many well-differentiated tumors remain indolent, whereas a subset progresses to aggressive, therapy-refractory phenotypes requiring improved molecular understanding and biomarkers. This review analyzes thyroid hormone (TH) signaling and the MAPK and PI3K/AKT pathways, emphasizing V600EBRAF-driven MAPK/ERK activation, dedifferentiation, metabolic rewiring, immune evasion, and targeted-therapy resistance, and highlights microRNAs as diagnostic, prognostic, and predictive markers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-determinants-of-thyroid-cancer-progression-thyroid-hormone-signaling-the-brafmapk-pathway-and-emerging-mirna-biomarkers/360243/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-determinants-of-thyroid-cancer-progression-thyroid-hormone-signaling-the-brafmapk-pathway-and-emerging-mirna-biomarkers/360243.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological factors drive thyroid cancer progression according to the review?","Question",{"text":112,"@type":113},"Progression is linked to the interplay between endocrine regulation, oncogenic signaling pathways, and tumor microenvironment dynamics, with tumor aggressiveness often supported by pathway activation and microRNA-mediated regulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the V600EBRAF mutation contribute to thyroid cancer aggressiveness?",{"text":117,"@type":113},"The review states that the V600EBRAF mutation acts as a central driver by sustaining MAPK/ERK signaling, promoting dedifferentiation, metabolic reprogramming, immune evasion, and resistance to targeted therapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do microRNAs (miRNAs) play in thyroid carcinogenesis and clinical use?",{"text":121,"@type":113},"The review highlights miRNAs as critical regulators of thyroid tumor biology and as promising diagnostic, prognostic, and predictive biomarkers, including potential value from clinical validation of miRNA-based panels and circulating miRNAs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360243,1790386730,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nMolecular Determinants of Thyroid Cancer Progression: Thyroid Hormone Signaling, the BRAF/MAPK Pathway, and Emerging miRNA Biomarkers  \nMarina Lasa 1,2 and Constanza Contreras-Jurado 1,3,4, *  \nAcademic Editor: Sonam Kumari  \nReceived: 16 March 2026  \nRevised: 16 April 2026  \nAccepted: 21 April 2026  \nPublished: 23 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM), Consejo Superior de Investigaciones Científicas—Universidad Autónoma de Madrid (CSIC_UAM), 28029 Madrid, Spain; [mlasa@iib.uam.es](mlasa@iib.uam.es)  \n2 Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, 28029 Madrid, Spain  \n3 Facultad de Ciencias Biomédicas y de la Salud, Universidad Alfonso X El Sabio, Villanueva de la Cañada, 28691 Madrid, Spain  \n4 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III,  \n28029 Madrid, Spain  \n* Correspondence: [sccontreras@iib.uam.es](sccontreras@iib.uam.es)  \nAbstract  \nThyroid cancer is the most common malignancy of the endocrine system and represents a biologically heterogeneous disease driven by the interplay between endocrine regulation, oncogenic signaling pathways, and tumor microenvironment dynamics. Although most follicular cell-derived thyroid cancers follow an indolent clinical course, a subset progresses toward aggressive, therapy-refractory phenotypes, underscoring the need for refined molecular understanding and improved biomarkers. This review comprehensively examines the molecular determinants of thyroid cancer progression, with particular emphasis on Thyroid Hormone (TH) signaling, the Mitogen-Activated Protein Kinase (MAPK) and Phosphoinositide 3-Kinase (PI3K)/AKT pathways, and the emerging role of microRNAs (miRNAs). We discuss how oncogenic alterations, most notably the V600EBRAF mutation, act as central drivers of tumor initiation and aggressiveness by sustaining MAPK/ERK signaling, promoting dedifferentiation, metabolic reprogramming, immune evasion, and resistance to targeted therapies. The cooperative role of PI3K/AKT signaling in reinforcing survival, invasion, and treatment resistance is highlighted, emphasizing the network-level integration of oncogenic pathways rather than linear dependency on single drivers. In parallel, thyroid hormones exert context-dependent effects on tumor biology through both genomic actions mediated by nuclear thyroid hormone receptors and non-genomic mechanisms initiated at the integrin αv β3 receptor, linking endocrine status to cancer progression and therapeutic response. Finally, we review the expanding evidence supporting miRNAsas critical regulators of thyroid carcinogenesis and as promising diagnostic, prognostic, and predictive biomarkers. The clinical validation of miRNA-based panels and circulating miRNAs offers new opportunities to improve preoperative risk stratification, reduce overtreatment, and guide personalized therapeutic strategies. Collectively, these insights support a multidimensional framework for understanding thyroid cancer progression and highlight future directions for precision oncology.  \nKeywords: thyroid cancer; thyroid hormones; MAPK; V600EBRAF; PI3K/AKT; miRNAs  \n1. Introduction  \n1.1. Thyroid Gland and Thyroid Hormones  \nThe thyroid gland is an endocrine organ located in the anterior neck below the larynx, composed of two lateral lobes connected by an H-shaped isthmus, giving it a butterfly-like appearance. Each lobe consists of numerous thyroid follicles, the structural and functional units of the gland, formed by follicular cells that secrete THs and store a substance called colloid containing thyroglobulin. Between the thyroid follicles are the parafollicular cells, or C cells, which secrete the polypeptide hormone calcitonin, whose m","cbCaikMKWeND5pC5","https://ap.wps.com/l/cbCaikMKWeND5pC5","pdf",713263,23,"English","# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Thyroid Gland and Thyroid Hormones","[{\"question\":\"What biological factors drive thyroid cancer progression according to the review?\",\"answer\":\"Progression is linked to the interplay between endocrine regulation, oncogenic signaling pathways, and tumor microenvironment dynamics, with tumor aggressiveness often supported by pathway activation and microRNA-mediated regulation.\"},{\"question\":\"How does the V600EBRAF mutation contribute to thyroid cancer aggressiveness?\",\"answer\":\"The review states that the V600EBRAF mutation acts as a central driver by sustaining MAPK/ERK signaling, promoting dedifferentiation, metabolic reprogramming, immune evasion, and resistance to targeted therapies.\"},{\"question\":\"What role do microRNAs (miRNAs) play in thyroid carcinogenesis and clinical use?\",\"answer\":\"The review highlights miRNAs as critical regulators of thyroid tumor biology and as promising diagnostic, prognostic, and predictive biomarkers, including potential value from clinical validation of miRNA-based panels and circulating miRNAs.\"}]","Molecular Determinants of Thyroid Cancer Progression - Thyroid Hormone Signaling, the BRAF/MAPK Pathway, and Emerging miRNA Biomarkers | PDF",1790139200,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e662120ac29c65b5befecf67ccfa8040.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/471614844bb448062348840f86894b20.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f50a535961806d0c6420bb6d8caf6ca.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5575f5dad040074db6ae7ee81505a58d.webp",980,1385]